Use of Ber-EP4 protein in recurrent metastatic basal cell carcinoma: A case report and review of the literature

International Journal of Dermatology

Volumn 43, Issue 8, 2004, Pages 600-603

  Saladi, Rao N ^a   Singh, Fiza ^a   Wei, Huachen ^a   Lebwohl, Mark G ^a   Phelps, Robert G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BER EP4; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTICLE; BASAL CELL CARCINOMA; CANCER SURGERY; CASE REPORT; CAUCASIAN; CELL NUCLEUS; CLINICAL FEATURE; EXCISION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; MEDICAL LITERATURE; METASTASIS; PROTEIN EXPRESSION; RECURRENT CANCER; SKIN BIOPSY; SKIN CANCER; SKIN ULCER; SOFT TISSUE; STROMA CELL; TUMOR CELL;

ANTIBODIES, MONOCLONAL; AXILLA; CARCINOMA, BASAL CELL; GENES, BCL-2; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 4444329250     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02192.x     Document Type: Article

References (41)

1. Rahbari H, Mehregan AH. Basal cell epitheliomas in usual and unusual sites. J Cutan Pathol 1979; 6: 425-431.
2. Johnson TM, Tschen J, Ho C, et al. Unusual basal cell carcinomas. Cutis 1994; 54: 85-92.
3. Betti R, Bruscagin C, Inselvini E, et al. Basal cell carcinomas of covered and unusual sites of the body. Int J Dermatol 1997; 36: 503-505.
4. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10: 1043-1046.
5. Gardner ES, Goldberg LH. Axillary basal cell carcinoma: literature survey and case report. Dermatol Surg 2001; 27: 966-968.
6. Malone JP, Fedok FG, Belchis DA, et al. Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature. Ear Nose Throat J 2000; 79 (511-5): 518-519.
7. Shelton RM. Skin cancer: A Review and atlas for the medical provider. Mount Sinai J Med 2001; 68: 243-247.
8. Berlin JM, Warner MR, Bailin PL. Metastatic basal cell carcinoma presenting as unilateral axillary lymphadenopathy: report of a case and review of the literature. Dermatol Surg 2002; 28: 1082-1084.
9. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer 1994; 73: 328-335.
10. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715-719.
11. Amonette RA, Salasche SJ, Chesney TM, et al. Metastatic basal-cell carcinoma. J Dermatol Surg Oncol 1981; 7: 397-400.
12. Miller SJ, Maloney ME. Cutaneous oncology. In: Pathophysilogy, Diagnosis and Management. Malden, MA: Blackwell Science, 1998: 612-660.
13. American Cancer Society's 2003 Facts & Figures.
14. Miller SJ, Maloney ME. Cutaneous oncology. In: Pathophysilogy, Diagnosis and Management. Malden, MA: Blackwell Science, 1998: 583-704.
15. Bozdogan O, Erkek E, Atasoy P, et al. bcl-2-related proteins, alpha-smooth muscle actin and amyloid deposits in aggressive and non-aggressive basal cell carcinomas. Acta Derm Venereol 2002; 82: 423-427.
16. Swanson PE, Fitzpatrick MM, Ritter JH, et al. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J Cutan Pathol 1998; 25: 153-159.
17. Poniecka AW, Alexis JB. An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol 1999; 21: 332-336.
18. Colombel M, Symmans F, Gills S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in harmone refractory human prostate cancer. Am J Pathol 1993; 143: 390.
19. Lu Q-L, Elia G, Lucas S. bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53: 29-35.
20. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
21. Chetty R, Dada MA, Gatter KC. bcl-2: Longevity personified!. Adv Anat Pathol 1997; 4: 134.
22. Xie X, Clausen OPF, De Angelis P, et al. The prognostic value of spontaneous apoptosis, Bax, bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-920.
23. Nakagawa K, Yamamura K, Maeda S, et al. bcl-2. expression in epidermal keratinocytic diseases. Cancer 1994; 74: 1720-1724.
24. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995; 17: 7-11.
25. Cerroni L, Kerl H. Aberrant bcl-2 protein expression provides a possible mechanism of neoplastic cell growth in cutaneous basal-cell carcinoma. J Cutan Pathol 1994; 21: 398-403.
26. Verhaegh ME, Sanders CJ, Arends JW, et al. Expression of the apoptosis-suppressing protein bcl-2 in non-melanoma skin cancer. Br J Dermatol 1995; 132: 740-74.
27. Wikonkal NM, Berg RJ, Van Haselen CW, et al. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133: 599-602.
28. Mooney EE, Ruis Peris JM, O'Neill A, et al. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48: 242-244.
29. Morales-Ducret CR, Van de Rijn M, et al. bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995; 131: 909-912.
30. Crowson AN, Magro CM, Kadin ME, et al. Differential expression of the bcl-2 oncogene in human basal cell carcinoma. Hum Pathol 1996; 27: 355-359.
31. Ramdial PK, Madaree A, Reddy R, et al. bcl-2 protein in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 2000; 27: 283-291.
32. Heyderman E, Graham RM, Chapman DV, et al. Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA), and Carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathol 1984; 8: 423-434.
33. Thomas P, Said JW, Nash G, et al. Profiles of keratin proteins in basal and squamous cell carcinomas of the skin. An immunohistochemical study. Lab Invest 1984; 50: 36-41.
34. Momburg F, Moldenhauer G, Hammerling GJ, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987; 47: 2883-2891.
35. Moldenhauer G, Momburg F, Moller P, et al. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987; 56: 714-721.
36. Latza U, Niedobitek G, Schwarting R, et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990; 43: 213-219.
37. Tellechea O, Reis JP, Domingues JC, et al. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol 1993; 15: 452-455.
38. Beer TW, Shepherd P, Theaker JM. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology 2000; 37: 218-223.
39. Yii NW, Niranjan NS. Metastatic basal cell carcinoma of the axilla: report of a case and construction with an island lateral pectorial flap. Ann Plast Surg 2000; 45: 78-82.
40. Jones MS, Helm KF, Maloney ME. The immunohistochemical characteristics of the basosquamous cell carcinoma. Dermatol Surg 1997; 23: 181-184.
41. Kist D, Perkins W, Christ S, et al. Anti-human epithelial antigen (Ber-EP4) helps define basal cell carcinoma masked by inflammation. Dermatol Surg 1997; 23: 1067-1070.